Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1205 - Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer


09 Oct 2016


Poster display


Hitomi Ajimizu


Annals of Oncology (2016) 27 (6): 455-461. 10.1093/annonc/mdw384


H. Ajimizu1, H. Ozasa2, S. Sato2, Y. Sakamori1, T. Funazo1, Y. Yasuda1, T. Nomizo1, T. Tsuji1, H. Yoshida1, Y. Yagi1, H. Nagai1, A. Sato1, M. Tsuchiya3, S. Muro1, Y. Nagasaka3, M. Mishima1, Y.H. Kim1

Author affiliations

  • 1 Respiratory Medicine, Kyoto University-Graduate school of medicine, 606-8507 - Kyoto/JP
  • 2 Respiratory Medicine, Kyoto University-Graduate school of medicine, Kyoto/JP
  • 3 Respiratory Medicine, Rakuwakai Otowa Hospital, Kyoto/JP


Abstract 1205


The prognosis of patients with advanced non-small cell lung

cancer (NSCLC) and coexisting chronic obstructive pulmonary disease (COPD) is uncertain. In addition, no previous studies have examined whether treating COPD improves the prognosis of such patients.


We focused our retrospective analysis on advanced NSCLC

patients who had received chemotherapy at Kyoto University Hospital between 2007 and 2014. The association between COPD treatment and overall survival (OS) was assessed using the log-rank test and Cox logistic regression models adjusted for age, sex, smoking, chemotherapy, the percentage forced expiratory volume in 1 second (%FEV1.0), and COPD treatment.


Of the 358 patients enrolled, 104 had COPD (COPD group) and

254 did not (non-COPD group). Thirty-seven patients in the COPD group had received COPD treatment. The median OS period was 323 days in the COPD group and 510 days in the non-COPD group (p 


Coexisting COPD was associated with worse survival

outcomes in patients with advanced NSCLC. Our analysis indicated that COPD treatment might have potential to salvage the prognosis of such patients.

Clinical trial identification

Legal entity responsible for the study

Kyoto University


Kyoto University


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings